| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $208.4M | +12.9% |
| SG&A Expense | $176.2M | +161.0% |
| Operating Income | -$384.6M | -52.6% |
| Interest Expense | $6.3M | -4.5% |
| Net Income | -$377.9M | -53.5% |
| EPS (Basic) | -$3.29 | -33.2% |
| EPS (Diluted) | -$3.29 | -33.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $323.5M | +81.9% |
| Short-term Investments | $44.0M | -83.0% |
| Current Assets | $385.1M | -14.6% |
| Total Assets | $404.3M | -14.9% |
| Current Liabilities | $55.4M | +18.1% |
| Long-term Debt | $99.7M | +98.8% |
| Total Liabilities | $158.8M | +49.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$300.0M | -49.3% |
| Capital Expenditures | $602K | +514.3% |
| Investing Cash Flow | $218.7M | +387.5% |
| Financing Cash Flow | $228.4M | -35.3% |
| Free Cash Flow | -$300.6M | -49.5% |
| Stockholders' Equity |
| $245.5M |
| -33.4% |